Europeanhhm

Cellistic Introduces Innovative iPSC-Based Platforms for Rapid Advancement and Production of Off-the-Shelf Allogeneic Cell Therapies

Tuesday, October 10, 2023

Cellistic, a provider of cell therapy platforms, has unveiled revolutionary pre-built cell line and manufacturing platforms designed to expedite the development and production of allogeneic cell therapies in a more cost-effective manner. These platforms, which rely on induced pluripotent stem cell (iPSC) technology, represent a significant advancement in reducing development time and enhancing cost-efficiency.

Gustavo Mahler, CEO of Cellistic, stressed the urgent need to reduce both the cost per dose and the time required for cell therapy development to make these therapies more accessible in healthcare. He believes that Cellistic's iPSC-based approach has the potential to achieve this by establishing a reliable and cost-efficient manufacturing process, ultimately speeding up the development of cell therapies.

Stefan Braam, Founder and CTO of Cellistic, highlighted the company's substantial investments in technology platforms dedicated to reducing development time and bringing high-quality, reproducible off-the-shelf cell therapies to the market. These platforms allow therapeutic partners to seamlessly integrate their own edits and target product profiles, accelerating their entry into the clinical phase. Unlike traditional approaches involving contract manufacturers, Cellistic's approach eliminates obstacles related to process transfer that can hinder the development timeline.

Cellistic's Pulse™ Cell Line and Echo™ Cell Therapy Manufacturing platforms, both based on iPSC technology, offer an efficient and robust solution for realizing off-the-shelf allogeneic cell therapies. In addition to these platforms, Cellistic provides comprehensive development support through its newly established GMP facility located on its campus in Mont-Saint-Guibert, Belgium.

Gustavo Mahler highlighted that the company is already collaborating with both autologous and allogeneic cell therapy partners to create off-the-shelf products based on next-generation iPSC technology using their platforms. This approach uniquely accelerates and simplifies the path to the clinical phase. The Cellistic team will actively participate in major cell therapy conferences to showcase their advancements in the field.

The company will attend significant events, including the Alliance for Regenerative Medicine's "Meeting on the Mesa" in Carlsbad, California, from October 10 to 12, 2023, and the European Society of Gene and Cell Therapy (ESGCT) conference in Brussels, Belgium, from October 24 to 27, 2023.

 

Source:businesswire.com

 

 

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024